Pfizer Inc. (NYSE:PFE) Shares Sold by Kazazian Asset Management LLC

Kazazian Asset Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 76.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,050 shares of the biopharmaceutical company's stock after selling 60,250 shares during the quarter. Kazazian Asset Management LLC's holdings in Pfizer were worth $457,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. LSV Asset Management increased its holdings in shares of Pfizer by 10.2% in the 1st quarter. LSV Asset Management now owns 15,153,114 shares of the biopharmaceutical company's stock valued at $383,980,000 after acquiring an additional 1,400,622 shares during the period. Mirabaud & Cie SA increased its holdings in shares of Pfizer by 9.9% in the 1st quarter. Mirabaud & Cie SA now owns 12,779 shares of the biopharmaceutical company's stock valued at $324,000 after acquiring an additional 1,150 shares during the period. Endeavor Private Wealth Inc. increased its holdings in shares of Pfizer by 969.2% in the 1st quarter. Endeavor Private Wealth Inc. now owns 9,345 shares of the biopharmaceutical company's stock valued at $237,000 after acquiring an additional 8,471 shares during the period. Signature Wealth Management Partners LLC increased its holdings in shares of Pfizer by 113.9% in the 1st quarter. Signature Wealth Management Partners LLC now owns 16,529 shares of the biopharmaceutical company's stock valued at $419,000 after acquiring an additional 8,800 shares during the period. Finally, Baker Avenue Asset Management LP increased its holdings in shares of Pfizer by 9.9% in the 1st quarter. Baker Avenue Asset Management LP now owns 28,727 shares of the biopharmaceutical company's stock valued at $728,000 after acquiring an additional 2,596 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Leerink Partners cut their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. TD Cowen cut their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Berenberg Bank cut their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Price Performance

Shares of NYSE PFE opened at $23.49 on Friday. The firm has a market capitalization of $133.55 billion, a P/E ratio of 17.02, a PEG ratio of 0.84 and a beta of 0.52. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.32. The company's fifty day moving average is $24.36 and its two-hundred day moving average is $24.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.